Jazz, which became an Irish company after its merger with Azur Pharma in 2012, has a drug portfolio focused on narcolepsy and hematology.
Looking for leads, investment insights, or competitive intelligence?
News about Jazz Pharmaceuticals
Overall deal value declined last year.
It'll give them some convenient cover for any bad news.
As drug stock prices tumble, one hedge fund manager's loss is another hedge fund manager's gain.
Investor Growth Capital will no longer make new U.S. investments.